Press Releases August 17, 2026 04:10 PM

Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor

Resmed appoints Carol Burt as new Lead Director as Ron Taylor retires after over two decades of service

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
RMD

Resmed announced that Carol Burt will become the Lead Director starting November 15, 2026, succeeding Ron Taylor who is retiring after more than 21 years on the board. Burt has been a board member since 2013 and chairs the Nominating and Governance Committee. The leadership transition is part of Resmed's continued strategic governance and long-term growth plan.

Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
RMD
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Carol Burt, current Nominating and Governance Chair, appointed as Lead Director effective November 15, 2026.
  • Ron Taylor retires after over 21 years of service and leadership on Resmed's board.
  • The leadership change supports Resmed's ongoing governance strategy to drive long-term value creation.
  • Nominating and Governance Chair Carol Burt to become Lead Director.
  • Ron Taylor to retire after more than 21 years of service on Resmed’s Board of Directors.

SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Carol Burt will become Lead Director on November 15, 2026. She will succeed Ron Taylor, Resmed’s current Lead Director, who is not standing for reelection at the company’s 2026 Annual Meeting of Stockholders on November 18, 2026, and will retire after more than 21 years of service to the company.

The Board has appointed Carol Burt to serve as Lead Director, effective November 15, 2026. Burt has served on Resmed’s Board since 2013 and currently chairs the Nominating and Governance Committee. She is also a member of the Audit Committee and the Compliance, Privacy and Quality Committee. Burt's extensive board leadership and governance experience position her well to serve as Lead Director as the company continues to execute its long-term strategy.

“Carol is an outstanding leader with deep governance experience, broad healthcare industry knowledge and a strong commitment to Resmed's mission,” said Mick Farrell, Resmed’s Chairman and CEO. “I look forward to continuing to work closely with Carol and the entire Board as we advance our strategy and create long-term value for our shareholders.”

Ron Taylor joined Resmed’s Board of Directors in 2005 and has served in numerous leadership roles, including as Lead Director since 2013. During his tenure, Ron helped guide the company's governance, strategy and long-term growth while providing thoughtful leadership and independent oversight during a period of significant growth and transformation.

“Ron has made extraordinary contributions to Resmed over the past two decades,” said Farrell. “His integrity, sound judgment and unwavering commitment to our patients, employees and shareholders have helped shape Resmed. On behalf of the Board and all Resmedians, I thank Ron for his outstanding service and wish him and his family all the very best.”

About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more at Resmed.com and follow @Resmed.

For Media
Brad Lotterman
[email protected]
[email protected]

For Investors 
Salli Schwartz
[email protected]
[email protected]  


Risks

  • Potential uncertainty or adjustment period due to the change in board leadership which could impact governance dynamics.
  • Any changes in board oversight might affect strategic decisions temporarily during the transition period.
  • Maintaining sustained innovation and market leadership could be challenged if governance shifts distract from operational focus.

More from Press Releases

California Water Service Group Named One of “World’s Greenest Companies” by Newsweek Aug 17, 2026 Terra Innovatum Global Reports Second Quarter 2026 Financial Results and Announces Webinar to Discuss Operational Progress Aug 17, 2026 HNI Corporation Announces Quarterly Dividend Aug 17, 2026 Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights Aug 17, 2026 CalPrivate Bank Announces Appointment of New Chief Credit Officer Aug 17, 2026